Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP

Last updated: December 4, 2024
Sponsor: University of Cologne
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Cablivi®

Clinical Study ID

NCT04985318
V01-19052020
  • Ages > 18
  • All Genders

Study Summary

The objective of this national, prospective, multi-centre observational study is to describe the prescription rational and practice in Germany, confirm the efficacy of caplacizumab in a real-world setting, and identify predicting factors in iTTP-patients with regard to persistent autoimmune activity, therapy guidance and risk of complications. The rational is to develop new treatment algorithms that optimize overall patient outcome and reduce treatment cost.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Confirmed diagnosis of an acute episode of acquired thrombotic thrombocytopenicpurpura

  • Treatment with at least one single dose of caplacizumab (10 mg i.v. or s.c.)

  • Male or female patients ≥ 18 years of age

  • signed written informed consent

Exclusion

Exclusion Criteria:

  • Hereditary thrombotic thrombocytopenic purpura

  • disability to give informed consent

Study Design

Total Participants: 350
Treatment Group(s): 1
Primary Treatment: Cablivi®
Phase:
Study Start date:
March 25, 2021
Estimated Completion Date:
December 12, 2034

Connect with a study center

  • University Hospital of Cologne

    Cologne, 50937
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.